https://www.siliconvalley.com/2024/11/12/bay-areas-23andme-cuts-40-of-its-workforce-and-discontinues-therapeutics-division/

NEW YORK  — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.

The latest restructuring efforts were announced by 23andMe on Monday. The company said it plans to wind down ongoing clinical trials “as quickly as practical” — and that it was currently evaluating “strategic alternatives” for assets related to its drug development and research programs, which include studies on potential cancer treatments.